Antibody-drug conjugate · Immune activation, directed at HER2 (ERBB2), TLR7 and TLR8 · developed by Bolt Biotherapeutics
Trastuzumab imbotolimod is an immune-stimulating antibody conjugate in which a trastuzumab-based antibody binds HER2 on tumor cells and carries a TLR7/8 dual agonist payload. The TLR7/8 agonist activates dendritic cells in the tumor microenvironment to stimulate antitumor immune responses. It is studied in HER2-positive and metastatic breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05954143 | Phase 2 | Metastatic Breast Cancer | Terminated | BOLT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
HER2-positive Breast CancerMetastatic Breast Cancer
Updated Nov 8, 2026. Something wrong or missing? Report it on the BOLT page.
See BOLT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BOLT catalysts and pipeline →